Differential Adherence to Free and Single-Pill Combination of Rosuvastatin/Ezetimibe: Findings from a Real-World Analysis in Italy

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2024-07-04 DOI:10.1007/s12325-024-02916-8

Leopoldo Perez de Isla, Evangelos Liberopoulos, Melania Dovizio, Chiara Veronesi, Luca Degli Esposti, Alberto Zambon

{"title":"Differential Adherence to Free and Single-Pill Combination of Rosuvastatin/Ezetimibe: Findings from a Real-World Analysis in Italy","authors":"Leopoldo Perez de Isla, Evangelos Liberopoulos, Melania Dovizio, Chiara Veronesi, Luca Degli Esposti, Alberto Zambon","doi":"10.1007/s12325-024-02916-8","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Adherence to cardiovascular drug treatment can significantly benefit from a reduced pill burden, but data on this matter derived from real-life settings are currently scanty. This analysis assessed the possible changes in adherence in patients treated with rosuvastatin and ezetimibe (ROS/EZE) as free multi-pill combination who switched to ROS/EZE as single-pill combination in the setting of real clinical practice in Italy.</p><h3>Methods</h3><p>A retrospective analysis was conducted on the administrative databases for a catchment area of about seven million health-assisted residents. Adults receiving ROS/EZE as a single-pill combination from January 2010 to June 2020 (followed up to 2021) were identified. The date of the first prescription of single-pill combination of ROS/EZE was considered as the index date. The analysis included the users of ROS/EZE as a free combination during the year before the index date. Baseline demographic and clinical characteristics were collected during the period of data availability prior to the index date. Adherence to therapy was evaluated as proportion of days covered (PDC), namely the percentage of days during which a patient had access to medication, in the 12-month interval preceding or following the index date (PDC < 25% non-adherence; PDC = 25–75% partial adherence; PDC > 75% adherence).</p><h3>Results</h3><p>A total of 1219 patients (61.1% male, aged 66.2 ± 10.4 years) were included. Cardiovascular comorbidities were found in 83.3% of them, diabetes in 26.4%, and a combination of both in 16.2%. Single-pill combination of ROS/EZE was associated with a higher proportion of adherent patients compared to free-pill combination (75.2% vs 51.8%, <i>p</i> < 0.001).</p><h3>Conclusions</h3><p>This real-world analysis suggested that switching from a regimen based on separate pills to one based on a single-pill combination resulted in improved adherence to ROS/EZE therapy.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11263226/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-024-02916-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Adherence to cardiovascular drug treatment can significantly benefit from a reduced pill burden, but data on this matter derived from real-life settings are currently scanty. This analysis assessed the possible changes in adherence in patients treated with rosuvastatin and ezetimibe (ROS/EZE) as free multi-pill combination who switched to ROS/EZE as single-pill combination in the setting of real clinical practice in Italy.

Methods

A retrospective analysis was conducted on the administrative databases for a catchment area of about seven million health-assisted residents. Adults receiving ROS/EZE as a single-pill combination from January 2010 to June 2020 (followed up to 2021) were identified. The date of the first prescription of single-pill combination of ROS/EZE was considered as the index date. The analysis included the users of ROS/EZE as a free combination during the year before the index date. Baseline demographic and clinical characteristics were collected during the period of data availability prior to the index date. Adherence to therapy was evaluated as proportion of days covered (PDC), namely the percentage of days during which a patient had access to medication, in the 12-month interval preceding or following the index date (PDC < 25% non-adherence; PDC = 25–75% partial adherence; PDC > 75% adherence).

Results

A total of 1219 patients (61.1% male, aged 66.2 ± 10.4 years) were included. Cardiovascular comorbidities were found in 83.3% of them, diabetes in 26.4%, and a combination of both in 16.2%. Single-pill combination of ROS/EZE was associated with a higher proportion of adherent patients compared to free-pill combination (75.2% vs 51.8%, p < 0.001).

Conclusions

This real-world analysis suggested that switching from a regimen based on separate pills to one based on a single-pill combination resulted in improved adherence to ROS/EZE therapy.

Abstract Image

查看原文本刊更多论文

瑞舒伐他汀/依折麦布免费和单药组合的不同依从性：意大利真实世界分析结果。

导言：减轻药片负担可显著提高心血管药物治疗的依从性，但目前从现实生活中获得的相关数据还很少。这项分析评估了在意大利实际临床实践中，使用罗伐他汀和依折麦布（ROS/EZE）免费多药组合治疗的患者转为使用罗伐他汀和依折麦布（ROS/EZE）单药组合治疗后在依从性方面可能发生的变化：我们对一个拥有约 700 万保健辅助居民的集水区的行政数据库进行了回顾性分析。研究确定了 2010 年 1 月至 2020 年 6 月（随访至 2021 年）期间接受 ROS/EZE 单药组合治疗的成年人。首次开具 ROS/EZE 单药组合处方的日期被视为指标日期。分析对象包括指数日期前一年内使用 ROS/EZE 免费复方制剂的患者。基线人口统计学特征和临床特征是在指数日期之前的数据可用期间收集的。治疗依从性以覆盖天数比例（PDC）进行评估，即在指数日期前后的 12 个月间隔内，患者可获得药物治疗的天数比例（PDC 75% 依从性）：共纳入 1219 名患者（61.1% 为男性，年龄为 66.2 ± 10.4 岁）。其中 83.3% 的患者合并有心血管疾病，26.4% 的患者合并有糖尿病，16.2% 的患者合并有这两种疾病。与自由丸联合用药相比，ROS/EZE 单丸联合用药的患者坚持用药的比例更高（75.2% vs 51.8%，p 结论：ROS/EZE 单丸联合用药的患者坚持用药的比例更高（75.2% vs 51.8%，p）：这项真实世界分析表明，从基于单独药片的治疗方案转变为基于单药片组合的治疗方案可提高 ROS/EZE 治疗的依从性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.